Page last updated: 2024-12-08
7-thiomethylspirolactone
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
7-thiomethylspirolactone: spironolactone metabolite; RN refers to (7alpha,17alpha)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 162325 |
| CHEMBL ID | 3544705 |
| SCHEMBL ID | 18157022 |
| MeSH ID | M0134860 |
Synonyms (35)
| Synonym |
|---|
| 7-thiomethylspirolactone |
| 7|a-thiomethyl spironolactone |
| (7r,8r,9s,10r,13s,14s,17r)-10,13-dimethyl-7-methylsulfanylspiro[2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene-17,5'-oxolane]-2',3-dione |
| 7-a-thiomethyl spironolactone |
| 7alpha-thiomethyl-sl |
| unii-0yu66jy4wl |
| 38753-77-4 |
| 7alpha-thiomethylspironolactone |
| pregn-4-ene-21-carboxylic acid, 17-hydroxy-7-(methylthio)-3-oxo-, gamma-lactone, (7alpha,17alpha)- |
| 7alpha-thiomethylspirolactone |
| 0yu66jy4wl , |
| 7a-thiomethylspironolactone |
| SC-26519 , |
| 7.alpha.-(thiomethyl)spirolactone |
| (7r,8r,9s,10r,13s,14s,17r)-10,13-dimethyl-7-methylsulfanyl-spiro(2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta(a)phenanthrene-17,5'-tetrahydrofuran)-2',3-dione |
| 7-de(acetylthio)-7.alpha.-(methylthio)spironolactone |
| spironolactone metabolite m4 |
| 7.alpha.-thiomethylspironolactone |
| 3-(3-oxo-7.alpha.-methylthio-17.beta.-hydroxy-4-androsten-17.alpha.-yl)propionic acid .gamma.-lactone |
| 7.alpha.-(methylthio)spironolactone |
| 7.alpha.-(thiomethyl)spironolactone |
| CHEMBL3544705 |
| (2'r,7r,8r,9s,10r,13s,14s)-10,13-dimethyl-7-(methylthio)-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3'h-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-3,5'(2h,4'h)-dione |
| SCHEMBL18157022 |
| 7-alpha-thiomethyl spironolactone |
| (2'r,7r,8r,10r,13s,14s)-10,13-dimethyl-7-(methylthio)-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3'h-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-3,5'(2h,4'h)-dione |
| AKOS032958181 |
| Q27237364 |
| 7 alpha -thiomethyl spironolactone |
| 17a-hydroxy-7a-(methylthio)-3-oxo-pregn-4-ene-21-carboxylic acid gamma-lactone |
| DTXSID80959567 |
| 10,13-dimethyl-7-(methylsulfanyl)-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-oxolane]-3,5'(2h)-dione |
| 7| inverted exclamation mark-(thiomethyl)spironolactone |
| 7?-thiomethyl spironolactone |
| PD151134 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Main pharmacokinetic parameters have been calculated using a biexponential (ALT and SPI) or a triexponential model (7TM and CAN)." | ( [Pharmacokinetics in healthy subjects of althiazide and spironolactone in a fixed combination for 2 doses]. Caplain, M; Capron, MH; Doignon, JL; Grognet, JM; Istin, M; Pelletier, B; Thébault, JJ; Wehrlen, M, ) | 0.13 |
| " Pharmacokinetic parameters were derived from the serum concentration-time course of each compound." | ( New insights into the pharmacokinetics of spironolactone. Hermens, WA; Merkus, FW; Overdiek, HW, 1985) | 0.27 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The mean (95% confidence limits) relative bioavailability for SP-COMP (compared with ALD) from steady state serum concentrations of canrenone, 6beta-hydroxyl 7alpha-thiomethyl spironolactone and 7alpha-thiomethyl spironolactone was 310." | ( Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: beta-cyclodextrin complex. Abosehmah-Albidy, AZ; Chrystyn, H; Losowsky, MS; Wong, V; York, P, 1997) | 0.3 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Our findings are contrary to the widely accepted belief that spironolactone is metabolized too rapidly to be detected in serum after oral dosing and that canrenone is the principal metabolite of spironolactone." | ( New insights into the pharmacokinetics of spironolactone. Hermens, WA; Merkus, FW; Overdiek, HW, 1985) | 0.27 |
| "Better absorption of spironolactone from the spironolactone: beta-cyclodextrin complex formulation should lead to a reduction in dosage and perhaps a more consistent effect in patients with chronic liver disease." | ( Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: beta-cyclodextrin complex. Abosehmah-Albidy, AZ; Chrystyn, H; Losowsky, MS; Wong, V; York, P, 1997) | 0.3 |
| " For investigation of bioequivalence of 2 oral spironolactone formulations, Spironolacton 50 Heumann and Aldactone 50, the pharmacokinetics and bioequivalence of the parent drug and 2 predominant active metabolites, canrenone and 7 alpha-thiomethylspirolactone, were determined in a 2-way crossover study in 24 young healthy male volunteers after multiple oral dosing of 100 mg once daily." | ( Analysis of metabolites--a new approach to bioequivalence studies of spironolactone formulations. Eichinger, A; Mahr, G; Martens, H; Metz, R; Nitsche, V; Vergin, H, 1997) | 0.3 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (12)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (41.67) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.47
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.47) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (30.77%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (69.23%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||